Addex Therapeutics Ltd

Stage 4 · Declining · week 41

As of Oct 22, 2026, Addex Therapeutics is in Stage 4, the downtrend phase, now in week 41 (since Jan 2, 2026). It closed at $2.89, 70.8% below its 52-week high and below its 200-day average, which is falling.

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. More about the company

$2.89

-3.28% today

$5.1M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ADXN early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 23w

S4 25w

S4 42w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 23w → S1 6w → S2 10w → S3 6w → S4 9w → S1 11w → S4 25w → S1 7w → S2 7w → S3 6w → S2 8w → S3 5w → S4 42w current

Total tracked: 166 weeks across 13 stage runs.

ADXN among Biotechnology420th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…420	ADXNAddex Therapeutics Ltd	Stage 4 · wk 41	16	−16.2%

vs 52W High

-70.8%

$2.65 lo$9.92 hi

70.8% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 41

1w13w26w

Week 41, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-51.4%

200 DMA: $5.95 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.01x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-16.2%

-50.9%

-52.9%

YTD

-64.3%

-68.7%

Scan Membership

Breakout Watch

Latest: 2024-03-11

4 appearances in last 60 days. First seen: 2020-12-29.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 41 · Vol 0.01x

2026-10-21S4

Wk 41 · Vol 0.00x

2026-10-20S4

Wk 41 · Vol 0.03x

2026-10-19S4

Wk 40 · Vol 0.02x

2026-10-16S4

Wk 40 · Vol 0.06x

2026-10-15S4

Wk 40 · Vol 0.21x

2026-10-14S4

Wk 40 · Vol 0.03x

2026-10-13S4

Wk 40 · Vol 0.01x

2026-10-12S4

Wk 39 · Vol 0.01x

2026-10-09S4

Wk 39 · Vol 0.03x

2026-10-08S4

Wk 39 · Vol 0.07x

2026-10-07S4

Wk 39 · Vol 0.05x

Moving averages & range

50 DMA

$3.64

200 DMA

$5.95

52W High

$9.92

52W Low

$2.65

5D Low

$2.76

Resistance levels (recent highs)

20d High

$3.65

60d High

$5.95

120d High

$7.01

250d High

$9.92

Next resistance

+26.2%

to 20d High

ROE

-150.6%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 1.3

Addex Therapeutics: quick answers

What stage is Addex Therapeutics in?

As of Oct 22, 2026, Addex Therapeutics (ADXN) is in Stage 4, the downtrend phase. It entered Stage 4 on Jan 2, 2026 and is in week 41. What the four stages mean

Is Addex Therapeutics in an uptrend?

No. Addex Therapeutics is in a Stage 4 downtrend. It trades 51.4% below its 200-day average, which is falling.

How far is Addex Therapeutics from its 52-week high?

Addex Therapeutics closed at $2.89 on Oct 22, 2026, 70.8% below its 52-week high of $9.92. Its 52-week low is $2.65.

How has Addex Therapeutics performed over the past year?

As of Oct 22, 2026, Addex Therapeutics is down 68.7% over the past year and down 64.3% so far in 2026.

Which sector and industry is Addex Therapeutics in?

Addex Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, addiction, chronic cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.